Is osimertinib effective?

As an important drug for targeted therapy of lung cancer, osimertinib has attracted much attention in clinical application.

Is osimertinib effective?

The therapeutic value of the drug can be systematically evaluated through multi-dimensional research data.

Clinical study data validation

The phase III FLAURA trial showed:

• Median progression-free survival for patients with advanced EGFR mutant lung cancer was 18.9 months

• The data for the first-generation TKI in the control group was 10.2 months

• Disease control rate increased to 78% in brain metastases subgroup

The study included 556 treatment-naïve patients with follow-up over 3 years.

Ability to control brain metastases

Osimertinib has unique penetrating properties to central nervous system lesions:

• Median survival of patients with brain metastases at baseline was extended to 15.2 months

• Brain lesions are reduced by more than 50% in 62% of cases

• 1-year survival rate for patients with meningeal metastases improved to 54%

These data are derived from a subgroup analysis of the AURA3 trial published in 2020.

Resistance management protocols

Mechanisms of acquired resistance:

• EGFR C797S mutation with osimertinib in combination with cetuximab

• Crizotinib in MET amplified patients increased to 33%

• Chemotherapy combined with immunotherapy is recommended for tissue transformation cases

These coping strategies have been incorporated in the 2022 NCCN Guidelines.

Guidelines for clinical application

Standardized use is key to achieving optimal treatment outcomes.

Genetic testing criteria

The following conditions must be met:

• Tissue biopsy confirming EGFR exon19del or L858R mutations

• Plasma ctDNA negative patients require secondary tissue validation

• Driver gene changes such as ALK/ROS1 were excluded

The sensitivity of the detection needs to be at the 1% mutation abundance threshold.

Dose adjustment regimen

Adjustment of dosing regimen in special cases:

• Dosing was suspended when the QT interval was prolonged > 500 ms

• Immediate and permanent discontinuation of the drug in the event of interstitial pneumonia

• Child-Pugh grade C for liver injury reduced to 40mg/day

These specifications are written in the 2023 version of the FDA drug insert.

Combination therapy exploration

Current research hotspots include:

• Extended resistance by 4.7 months in combination with bevacizumab

• Sequential radiotherapy improves local lesion control by 29%

• Neoadjuvant therapy achieved a pathologic complete response rate of 31%.

These innovative solutions are being validated in Phase III clinical trials.

Osimertinib has shown significant advantages in the treatment of EGFR mutant lung cancer, and its rational application needs to be combined with accurate detection, standardized medication and individualized strategies. Clinical practice should continue to pay attention to the latest research progress and optimize the treatment plan.